Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer

KATSUHIKO MASUDO, NOBUYASU SUGANUMA, HIROTAKA NAKAYAMA, TAKASHI OSHIMA, YASUSHI RINO, HIROYUKI IWASAKI, KENICHI MATSUZU, KIMINORI SUGINO, KOICHI ITO, TETSUO KONDO, YOSHIYASU NAKAMURA, MITSUYO YOSHIHARA, MUNETAKA MASUDA and YOHEI MIYAGI
In Vivo January 2018, 32 (1) 25-31;
KATSUHIKO MASUDO
1Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NOBUYASU SUGANUMA
1Department of Surgery, Yokohama City University, Yokohama, Japan
2Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: n-suga@vesta.dti.ne.jp
HIROTAKA NAKAYAMA
1Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI OSHIMA
1Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUSHI RINO
1Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROYUKI IWASAKI
2Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENICHI MATSUZU
3Department of Surgery, Ito Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KIMINORI SUGINO
3Department of Surgery, Ito Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOICHI ITO
3Department of Surgery, Ito Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TETSUO KONDO
4Department of Human Pathology, University of Yamanashi, Yamanashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIYASU NAKAMURA
5Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MITSUYO YOSHIHARA
5Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MUNETAKA MASUDA
1Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOHEI MIYAGI
5Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Enhancer of zeste homolog 2 (EZH2) is a member of the polycomb group of genes, which are key factors in the regulation of cell proliferation and differentiation. EZH2 is overexpressed in many malignancies. We analyzed EZH2 protein expression levels in different histological subtypes of thyroid cancer to examine its utility as a prognostic factor. Materials and Methods: We examined EZH2 protein expression by immunohistochemistry in tissue samples from 67 cases of poorly differentiated (PDTC) and 48 cases of anaplastic thyroid carcinoma (ATC), and in samples of adjacent normal and differentiated thyroid carcinoma (DTC). We examined differences in expression of EZH2 among various histological types of thyroid cancer, and the relationship between EZH2 expression and patient outcome. Results: EZH2 protein was expressed in PDTC and ATC, but not in normal thyroid gland or DTC. EZH-positivity increased in the order of DTC, PDTC, and ATC (p<0.01). Higher EZH2 expression correlated with poorer survival in PDTC (p=0.004), and a similar but non-significant trend was observed in ATC (p=0.166). Multivariate analysis identified EZH2 as an independent prognostic factor similar to metastatic status in the Japanese Society of Thyroid Surgery (JSTS) classification of PDTC. Conclusion: EZH2 overexpression is associated with malignant potential in thyroid cancer, and may thus be a useful prognostic marker of aggressive thyroid cancer.

  • Thyroid cancer
  • EZH2
  • prognostic factor
  • epigenetics

Thyroid cancer is the most common malignancy of the endocrine system, with an apparently increasing incidence associated with the widespread use of imaging studies (1, 2). The lifetime risk of thyroid cancer is approximately 1.1%, but the 5-year survival rate has risen to 97.8% because almost 70% of cases are now diagnosed at an early stage while the cancer remains localized to the thyroid gland (3). There are five main histological types of thyroid carcinoma: papillary (PTC), follicular (FTC), medullary, poorly-differentiated (PDTC), and anaplastic thyroid carcinoma (ATC) (4). PTC and FTC are the most common types of thyroid cancer; these are considered as well-differentiated thyroid carcinomas (DTCs) and have a very good prognosis. In contrast, ATC is relatively rare; it accounts for only 1-2% of all thyroid cancers and has an extremely poor prognosis (5), with 6-month and 1-year cause-specific survival rates for common-type ATC of 36% and 18% (6). PDTC is a malignant tumor showing intermediate traits between DTC and ATC. Three types of PDTC have been defined by the Japanese Society of Thyroid Surgery (JSTS) criteria, World Health Organization (WHO) classification, and Turin proposal. The 6th edition of the General Rules for the Description of Thyroid Cancer by the JSTS (7) defined PDTC as a tumor with only a small poorly differentiated compartment, showing insular, trabecular, solid, or scirrhous growth patterns, based on the proposal by Sakamoto et al. (8). The WHO definition of PTCD (4) is a tumor with insular, trabecular, or solid patterns in most of the tumor, together with an infiltrative pattern of growth, necrosis, and obvious vascular invasion. The Turin diagnostic criteria for PTCD include the presence of insular/trabecular/solid growth pattern, absence of conventional nuclear features of papillary carcinoma, and the presence of at least one of convoluted nuclei, mitotic activity ≥3×10/high-power field, or tumor necrosis (9). The prevalence decreases and the prognosis worsens in the order JSTS, WHO, Turin (10).

Enhancer of zeste homolog 2 (EZH2) is a well-known histone modifier protein that functions as a methyltransferase at lysine 27 of histone H3 (11). EZH2 is a member of the polycomb group of genes (12), which is important for transcriptional regulation through chromatin remodelling, nucleosome modification, and interactions with other transcription factors. EZH2 is presumed to promote cancer progression by transcriptional repression of tumour suppressors and by maintaining cells in a stem-cell-like state (13, 14). EZH2 has been shown to be overexpressed in many types of malignancies, including prostate, bladder, breast, lung, gastric, and brain cancers and has been suggested as a candidate prognostic factor and therapeutic target (15, 16).

In thyroid cancer, high EZH2 expression levels have been detected in ATC, with no expression in normal thyroid and low expression in DTC (17). More aggressive disease, such as the occurrence of metastases in medullary thyroid carcinoma, was associated with significantly increased EZH2 gene expression, which did not correlate with the mutational statuses of the RET or RAS genes (18). However, there is currently no information on the expression of EZH2 in PDTC or on the relationship between EZH2 expression and prognosis in the different pathological types of PDTC.

This study aimed to analyze the expression levels of EZH2 protein in different histological types of thyroid cancer, correlate these expression levels with various clinicopathological factors, and examine the utility of EZH2 as a prognostic factor in patients with thyroid cancer.

Materials and Methods

Patients and samples. We retrospectively examined surgical specimens of thyroid tumors from patients who underwent surgery at Kanagawa Cancer Centre and Ito Hospital between December 1977 and March 2013. EZH2 expression was examined by immunohistochemistry in tissue samples from 67 cases of PDTC (defined by the JSTS 6th edition), 48 cases of ATC, and in 30 samples of adjacent normal and differentiated thyroid carcinoma tissue which come from some of the above PDTC/ATC patients.

The study protocol was approved by the Ethics Committees of the Kanagawa Cancer Centre and Ito Hospital.

Tissue microarrays. Archival hematoxylin and eosin-stained slides of the samples were retrieved and reviewed to confirm the pathological features and select suitable tissue blocks for immunohistochemistry analysis. We constructed tissue microarrays (TMAs) using PDTC, ATC, and the adjacent normal and DTC lesions. TMAs consisting of cores, each measuring 4 mm in diameter, were assembled from formalin-fixed, paraffin-embedded blocks of surgical samples of primary thyroid tumors. The array included tissue cores from 68 PDTC, 48 ATC, and 30 adjacent normal and DTC tissues as a control.

Immunohistochemistry. Immunohistochemical staining for EZH2 was performed in all cases. TMAs were cut into 4-μm-thick sections and mounted on pre-coated glass slides. All sections were stained with primary antibodies to EZH2 (clone D2C9, dilution 1:50; Cell Signaling Technology Inc., Danvers, MA, USA) using an autostainer (Histostainer; Nichirei Biosciences Inc., Tokyo, Japan) (19).

Immunohistochemical scoring was based on semi-quantitative assessment of the intensity of nuclear staining (graded as 0, no staining; 1+, weak; 2+, medium; and 3+, strong) and the percentage of positive cells. Positive staining was defined by strong staining (2+ or 3+) and a high percentage positivity ≥10% (Figure 1).

The immunohistochemistry results were assessed in a blinded fashion by pathologists (Y.M. and T.K.) and a thyroid surgeon (N.S.) who examined each slide independently. Unclear cases were discussed between the pathologists and thyroid surgeon.

Follow-up. Follow-up data were obtained from the Kanagawa Cancer Centre and Ito Hospital registries until December 31, 2016. Active follow-up was conducted by accessing hospital-visit records, resident registration cards, and permanent-domicile data. During the study period, four subjects (3.4%; 4/115) were lost to follow-up. Overall survival (OS) was defined as the period from the day of diagnosis of the primary lesion until the day of death. The median follow-up time was 39 months [PDTC; 59 (range=8-122 months) months, ATC; 4 (range=0-151 months) months] after diagnosis of the primary lesion.

Statistical analyses. The comparison of patient characteristics among each pathological subtype was used Mann-Whitney U-test. Positive rates of EZH2 expressions in normal and neoplastic thyroid tissues, and associations between clinicopathological factors and EZH2 expression were analysed by chi-square test. OS was analysed using the Kaplan–Meier method, and Cox proportional hazards models were applied to the multivariate analyses. Correlations between EZH2 expression and clinicopathological factors were evaluated using Pearson's product-moment correlation coefficients (r). A p-value <0.05 was considered statistically significant for all statistical analysis. All statistical analyses were performed using SPSS version 20 (SPSS Inc., Chicago, IL, USA).

Ethical approval. All procedures performed in studies involving human participants were performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent. Informed and signed consent was obtained from all individual participants included in the study.

Results

Clinicopathological characteristics of all patients. The tissue samples were obtained from 67 cases of JSTS, 37 cases of WHO and 12 cases of Turin PDTC, 48 cases of ATC, and in 30 samples of adjacent normal and differentiated thyroid carcinoma tissue which come from some of the above PDTC/ATC patients. The patient characteristics are summarized in Table I. The mean ages of the study subjects were 55 years (range=19-83 years) for JSTS, 53 years (range=9-83 years) for WHO, and 58 years (range=29-72 years) for Turin PDTCs, and 68 years (range=48-90 years) for ATC. There were significant differences in age between PDTC and ATC (JSTS vs. ATC/WHO vs. ATC/Turin vs. ATC=p<0.001/p<0.001/p=0.033, respectively), but no significant differences among the three pathological types of PDTC. There were no significant differences between any of the four groups (JSTS, WHO, Turin, and ATC) in terms of sex or M status.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Representative breast tissue sections stained with EZH2 antibody. Immunohistochemical scoring was done by semi-quantitative assessment of the intensity of nuclear staining (graded as 0, no staining; 1+, weak; 2+, median; and 3+, strong) and the percentage of positive cells. Positive staining was defined by strong staining (2+ or 3+) and high percentage positivity ≥10%.

EZH2 status in each pathological type. EZH2 expression was evaluated by immunohistochemistry using paraffin-embedded sections of normal and carcinoma thyroid tissues. Representative images and the EZH2-positivity of each pathological type are shown in Figure 2. EZH2 protein expression was detected in 87.5% (42/48) of ATC cases, but in no normal thyroid or DTC samples. EZH2 protein expression was detected in 17.9% (12/67) of JSTS, 21.6% (8/37) of WHO, and 25.0% (3/12) of Turin PDTCs, with a significant increase in the order DTC<PDTC<ATC (p<0.01).

Associations between clinicopathological factors and EZH2 expression. The associations between clinicopathological factors and EZH2 expression are shown in Table II. EZH2 showed no significant association with any factors in JSTS and Turin criteria PDTC or ATC, but high expression of EZH2 was associated with smaller tumor diameter in WHO classification PDTC. There was no significant difference in EZH2 expression or T status between JSTS and Turin criteria PDTC.

Relationship between EZH2 expression and patient outcome. Univariate analysis showed that high EZH2 expression was a poor prognostic indicator of OS in JSTS classification PDTC compared with low EZH2 expression (hazard ratio (HR) 9.1; 95% confidence interval (CI) 1.6-50.1, p=0.011). However, high EZH2 expression was not a poor prognostic indicator of OS in ATC (HR 1.9; 95%CI=0.7-4.9, p=0.185) (Table III), WHO PDTC (HR 4.2; 95%CI=0.6-27.0, p=0.137), or Turin PDTC (HR 434; 95%CI=0.0-9.0×1012, p=0.616) (data not shown). High expression of EZH2 was also identified as a prognostic factor in multivariate analysis of JSTS classification PDTC (HR 9.0; 95%CI=1.5–55.4, p=0.018), while M1 status was a poor prognostic factor in univariate and multivariate analyses of JSTS PDTC. No prognostic factors were identified for the WHO and Turin PDTC classifications. T4b and M1 status were poor prognostic factors in ATC in univariate and multivariate analyses. No factors were significantly correlated with EZH2 expression in JSTS classification PDTC, whereas tumor (T) and extra thyroidal extension (Ex) were weakly correlated with EZH2 in ATC (r=0.379, p=0.008; r=0.303, p=0.037, respectively). EZH2 was an independent prognostic factor similar to M status in JSTS classification PDTC. The estimated 5-year survival rates in the low-EZH2-expression group were significantly higher compared with the high-expression group in all patients (91.3% vs. 57.1%, p=0.002, Figure 3a) and in M1 patients (83.3% vs. 40.0%, p=0.008) (Figure 3b) with JSTS PDTC.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patient characteristics

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Immunohistochemical analysis of EZH2 expression in normal and neoplastic thyroid tissues. EZH2-positivity increased in the order DTC, PDTC (JSTS, WHO, Turin), and ATC.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Kaplan–Meier survival curves for JSTS criteria PDTC with high and low EZH2 expression. The estimated 5-year survival rates in the low-expression group were significantly higher compared to the high-expression group for (a) all patients (91.3% vs. 57.1%, p=0.002) and (b) M1 patients (83.3% vs. 40.0%, p=0.008).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Associations between clinicopathological factors and EZH2 expression.

Discussion

Three types of PDTC have been defined by the JSTS 6th edition based on the proposal by Sakamoto et al., WHO classification, and Turin proposal, respectively. Ito et al. investigated the prevalence and clinical significance of these three types (10) and confirmed that the prevalence of PDTC decreased in the order JSTS, WHO, Turin (11.1%, 0.8%, 0.3%, respectively), while the prognosis worsened in the same order (10-year cause-specific survival: 94.2%, 80.0%, 60.0%, respectively). The current study confirmed these tendencies regarding the prevalence and prognosis. Although there was no significant difference among three types of PDTC, EZH2 protein expression tended to increase in the order JSTS (17.9%), WHO (21.6%), and Turin (25.0%), in contrast to the prevalence and prognosis, while EZH2-positivity increased significantly in the order DTC, PDTC, and ATC, consistent with the prognosis of thyroid cancer. The current study provides the first evidence to suggest that EZH2 expression may be an independent prognostic factor similar to metastasis, especially in JSTS PDTC.

Various possible mechanisms for EZH2 up-regulation have been revealed in different malignant tumors. The pRB–E2F pathway regulates EZH2 expression by transcriptional activation and leads to tumor cell proliferation (20). In metastatic breast cancer, endothelial growth factor receptor endocytosis was suppressed, leading to EZH2 overexpression through up-regulation of the MEK–ERK–Elk-1 pathway (21), with subsequent effects of the up-regulated EZH2 on cancer proliferation. EZH2 has also been shown to repress the expression of classic tumor suppressor genes such as CDKN2A and p53 (22) directly, and to reduce the levels of RAD51 leading to the activation of Raf1/ERK and β-catenin signalling (23). Several reports have revealed that EZH2 affects not only genetic but also epigenetic pathways. The loss of micro RNAs such as miR-26a, miR-101, and miR214 resulted in EZH2 accumulation (24-25), while down-regulation of miR-25 and miR-30d could contribute to thyroid cancer progression, leading to the development of anaplastic carcinomas targeting EZH2 mRNA (26).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Relationship between EZH2 expression and patient outcome.

Thyroid cancer is difficult to treat using conventional treatments. Some tyrosine-kinase inhibitors are currently available on the market, but new therapies are still needed. Inari et al. demonstrated a significant correlation between EZH2 expression and Ki-67 expression scores in breast cancer, suggesting that EZH2 may represent a potential therapeutic target for aggressive breast cancers exhibiting high Ki-67 expression, thus warranting further investigations. Furthermore, several EZH2 inhibitors have recently been developed and have yielded promising results in small cell lung cancer cell lines and malignant rhabdoid tumors (27).

Conclusion

EZH2-positivity increases in the order of DTC, PDTC, and ATC, and high EZH2 expression appears to be a poor prognostic indicator of OS in JSTS classification PDTC. EZH2 overexpression may be associated with the malignant potential of thyroid cancers, and may thus be a useful prognostic marker for aggressive behaviour of these cancers. EZH2 may also represent a potential therapeutic target for aggressive thyroid cancers.

Acknowledgements

This work was supported by grants from the MEXT/JSPS KAKENHI Grant Number JP 26461954. The Authors would like to express their gratitude to the staff in the Departments of Pathology, Kanagawa Cancer Centre and Ito Hospital for their technical assistance and for collecting cancer tissues. The Authors would also like to thank Susan Furness, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Footnotes

  • ↵* These Authors contributed equally to this study.

  • This article is freely accessible online.

  • Conflicts of Interest

    The Authors have no conflicts of interest to declare.

  • Received November 1, 2017.
  • Revision received November 21, 2017.
  • Accepted November 23, 2017.
  • Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Davies L,
    2. Welch HG
    : Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167, 2006.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Ahn HS,
    2. Kim HJ,
    3. Welch HG
    : Korea's thyroid-cancer “epidemic”-screening and overdiagnosis. N Engl J Med 371: 1765-1767, 2014.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Nguyen QT,
    2. Lee EJ,
    3. Huang MG,
    4. Park YI,
    5. Khullar A,
    6. Plodkowski RA
    : Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits 8: 30-40, 2015.
    OpenUrl
  4. ↵
    1. DeLeillis RA,
    2. Lloyd RV,
    3. Heitz PU,
    4. et al
    1. Sobrinho-Simoes M,
    2. Carcangiu ML,
    3. Albores-Saavedra J
    : Poorly differentiated carcinoma. In: Pathology and Genetics of Tumours of Endocrine Organs. DeLeillis RA, Lloyd RV, Heitz PU, et al. (eds.). Lyon, IARC Press, pp. 73-76, 2004.
  5. ↵
    1. Smallridge RC,
    2. Copland JA
    : Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol 6: 486-497, 2010.
    OpenUrl
  6. ↵
    1. Sugitani I,
    2. Miyauchi A,
    3. Sugino K,
    4. Okamoto T,
    5. Yoshida A,
    6. Suzuki S
    : Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 36: 1247-1254, 2012.
    OpenUrlCrossRefPubMed
  7. ↵
    The Japanese Society of Thyroid Surgery General Rules for the Description of Thyroid Cancer (6th edition). Tokyo, Kanehara Press (In Japanese), 2005.
  8. ↵
    1. Sakamoto A,
    2. Kasai N,
    3. Sugano H
    : Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high risk group of papillary and follicular carcinomas. Cancer 52: 1849-1855, 1983.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Volante M,
    2. Collini P,
    3. Nikiforov YE,
    4. Sakamoto A,
    5. Kakudo K,
    6. Katoh R,
    7. Lloyd RV,
    8. LiVolsi VA,
    9. Papotti M,
    10. Sobrinho-Simoes M,
    11. Bussolati G,
    12. Rosai J
    : Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31: 1256-1264, 2007.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Ito Y,
    2. Hirokawa M,
    3. Fukushima M,
    4. Inoue H,
    5. Yabuta T,
    6. Uruno T,
    7. Kihara M,
    8. Higashiyama T,
    9. Takamura Y,
    10. Miya A,
    11. Kobayashi K,
    12. Matsuzuka F,
    13. Miyauchi A
    : Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan. World J Surg 32: 1535-1543, 2008.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Cao R,
    2. Wang L,
    3. Wang H,
    4. Xia L,
    5. Erdjument-Bromage H,
    6. Tempst P,
    7. Jones RS,
    8. Zhang Y
    : Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298: 1039-1043, 2002.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Schuettengruber B,
    2. Chourrout D,
    3. Vervoort M,
    4. Leblanc B,
    5. Cavalli G
    : Genome regulation by polycomb and trithorax proteins. Cell 128: 735-745, 2007.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Boyer LA,
    2. Plath K,
    3. Zeitlinger J,
    4. Brambrink T,
    5. Medeiros LA,
    6. Lee TI,
    7. Levine SS,
    8. Wernig M,
    9. Tajonar A,
    10. Ray MK,
    11. Bell GW,
    12. Otte AP,
    13. Vidal M,
    14. Gifford DK,
    15. Young RA,
    16. Jaenisch R
    : Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441: 349-353, 2006.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Levine SS,
    2. Weiss A,
    3. Erdjument-Bromage H,
    4. Shao Z,
    5. Tempst P,
    6. Kingston RE
    : The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol Cell Biol 22: 6070-6078, 2002.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Asangani IA,
    2. Ateeq B,
    3. Cao Q,
    4. Dodson L,
    5. Pandhi M,
    6. Kunju LP,
    7. Mehra R,
    8. Lonigro RJ,
    9. Siddiqui J,
    10. Palanisamy N,
    11. Wu YM,
    12. Cao X,
    13. Kim JH,
    14. Zhao M,
    15. Qin ZS,
    16. Iyer MK,
    17. Maher CA,
    18. Kumar-Sinha C,
    19. Varambally S,
    20. Chinnaiyan AM
    : Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell 49: 80-93, 2013.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Kondo Y
    : Targeting histone methyltransferase EZH2 as cancer treatment. J Biochem 156: 249-257, 2014.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Borbone E,
    2. Troncone G,
    3. Ferraro A,
    4. Jasencakova Z,
    5. Stojic L,
    6. Esposito F,
    7. Hornig N,
    8. Fusco A,
    9. Orlando V
    : Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. J Clin Endocrinol Metab 96: 1029-1038, 2011.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Sponziello M,
    2. Durante C,
    3. Boichard A,
    4. Dima M,
    5. Puppin C,
    6. Verrienti A,
    7. Tamburrano G,
    8. Di Rocco G,
    9. Redler A,
    10. Lacroix L,
    11. Bidart JM,
    12. Schlumberger M,
    13. Damante G,
    14. Russo D,
    15. Filetti S
    : Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. Mol Cell Endocrinol 392: 8-13, 2014.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Inari H,
    2. Suganuma N,
    3. Kawachi K,
    4. Yoshida T,
    5. Yamanaka T,
    6. Nakamura Y,
    7. Yoshihara M,
    8. Nakayama N,
    9. Yamanaka A,
    10. Masudo K,
    11. Oshima T,
    12. Yokose T,
    13. Rino Y,
    14. Shimizu S,
    15. Miyagi Y,
    16. Masuda M
    : Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions. BMC Cancer 17: 160-174, 2017.
    OpenUrl
  20. ↵
    1. Adrian P,
    2. Bracken AP,
    3. Pasini D,
    4. Capra M,
    5. Prosperini E,
    6. Colli E,
    7. Helin K
    : EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22: 5323-5335, 2003.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. S Fujii K,
    2. Tokita K,
    3. Wada N,
    4. Ito K,
    5. Yamauchi C,
    6. Ito Y,
    7. Ochiai A
    : MEK–ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene 30: 4118-4128, 2011.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Kazanets A,
    2. Shorstova T,
    3. Hilmi K,
    4. Marques M,
    5. Witcher M
    : Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential. Biochim Biophys Acta 1865: 275-288, 2016.
    OpenUrl
  23. ↵
    1. Yoo KH,
    2. Hennighausen L
    : EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci 8: 59-65, 2012.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Dang X,
    2. Ma A,
    3. Yang L,
    4. Hu H,
    5. Zhu B,
    6. Shang D,
    7. Chen T,
    8. Luo Y
    : MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet 205: 113-123, 2012.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Derfoul A,
    2. Juan AH,
    3. Difilippantonio MJ,
    4. Palanisamy N,
    5. Ried T,
    6. Sartorelli V
    : Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis 32: 1607-1614, 2011.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Esposito F,
    2. Tornincasa M,
    3. Pallante P,
    4. Federico A,
    5. Borbone E,
    6. Pierantoni GM,
    7. Fusco A
    : Down-Regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab 97: E710-718, 2012.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Knutson SK,
    2. Warholic NM,
    3. Wigle TJ,
    4. Klaus CR,
    5. Allain CJ,
    6. Raimondi A,
    7. Porter Scott M,
    8. Chesworth R,
    9. Moyer MP,
    10. Copeland RA,
    11. Richon VM,
    12. Pollock RM,
    13. Kuntz KW,
    14. Keilhack H
    : Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA 110: 7922-7927, 2013.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

In Vivo: 32 (1)
In Vivo
Vol. 32, Issue 1
January-February 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer
KATSUHIKO MASUDO, NOBUYASU SUGANUMA, HIROTAKA NAKAYAMA, TAKASHI OSHIMA, YASUSHI RINO, HIROYUKI IWASAKI, KENICHI MATSUZU, KIMINORI SUGINO, KOICHI ITO, TETSUO KONDO, YOSHIYASU NAKAMURA, MITSUYO YOSHIHARA, MUNETAKA MASUDA, YOHEI MIYAGI
In Vivo Jan 2018, 32 (1) 25-31;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer
KATSUHIKO MASUDO, NOBUYASU SUGANUMA, HIROTAKA NAKAYAMA, TAKASHI OSHIMA, YASUSHI RINO, HIROYUKI IWASAKI, KENICHI MATSUZU, KIMINORI SUGINO, KOICHI ITO, TETSUO KONDO, YOSHIYASU NAKAMURA, MITSUYO YOSHIHARA, MUNETAKA MASUDA, YOHEI MIYAGI
In Vivo Jan 2018, 32 (1) 25-31;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Prognostic Factors and Survival Score for Patients With Anaplastic Thyroid Carcinoma: A Retrospective Study from a Regional Registry
  • EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment
  • Prognostic Value of Age and Distant Metastasis in Differentiated Thyroid Carcinoma Undergoing Salvage Surgery
  • A system biology approach reveals cellular pathway differences between follicular thyroid carcinoma and follicular thyroid adenoma
  • Performance Status and Number of Metastatic Extra-cerebral Sites Predict Survival After Radiotherapy of Brain Metastases from Thyroid Cancer
  • Google Scholar

More in this TOC Section

  • Non-invasively Imageable Tibia-tumor-fragment Implantation Experimental-bone-metastasis Mouse Model of GFP-expressing Prostate Cancer
  • Protective Effects of Gamma-mangostin on Hydrogen Peroxideinduced Cytotoxicity in Human Retinal Pigment Epithelial Cells
  • The First Mouse Model of Meckel’s Diverticulum Carcinoma
Show more Experimental Studies

Similar Articles

Keywords

  • thyroid cancer
  • EZH2
  • prognostic factor
  • epigenetics
In Vivo

© 2022 In Vivo

Powered by HighWire